X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizophrenia in adults.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition March 18, 2024
Details:
Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizophrenia in adults.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition December 22, 2023
Details:
KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $460.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 24, 2023
Details:
Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $500.0 million Upfront Cash: $100.0 million
Deal Type: Agreement March 23, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs & Co. LLC
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 21, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
